Inh: Clinical Trials

9 trials of Inh, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 not yet recruiting, 1 recruiting, 1 suspended. 9 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 4, Not yet recruiting 1, Recruiting 1, Suspended 1, Terminated 1, Unknown 1
Phase 12Completed 1, Recruiting 1
Phase 31Completed 1

Follow Inh: new trials by email Literature Review of Inh trials Research Report on Inh

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Rifapentine, Isoniazid, Dolutegravir - Tuberculosis
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)1442026-09-282026-11-02
Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis
Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis
Phase 2Not yet recruitingShanghai Pulmonary Hospital, Shanghai, China452025-08-202025-08-19
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis
Phase 2SuspendedNational Institute of Allergy and Infectious Diseases (NIAID)3412025-03-112026-11-02
Pharmacogenetics-guided Isoniazid Dosing in TB-HIV
Isoniazid Tablets - Tuberculosis
Phase 2UnknownMakerere University402021-12-072022-01-25
Tuberculosis Clinical Trials Consortium Study 35
Rifapentine, Isoniazid - Latent Tuberculosis
Phase 1 / Phase 2CompletedCenters for Disease Control and Prevention692019-11-122026-07-24
Infant TB Infection Prevention Study
Isoniazid - Tuberculosis
Phase 2CompletedUniversity of Washington3002016-08-012023-04-28
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis
Phase 2 / Phase 3CompletedUniversity of Cape Town1542015-11-122021-09-29
High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)
Isoniazid, Vitamin B6 - Tuberculosis
Phase 2CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections2822014-08-132023-02-17
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir - HIV Infection, Tuberculosis
Phase 2TerminatedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections712013-07-132018-02-13

Conditions studied

Tuberculosis (6)  ·  Latent Tuberculosis (2)  ·  Tuberculosis, Pulmonary (2)  ·  Extensively Drug-Resistant Tuberculosis (1)  ·  HIV Infections (1)  ·  Tuberculosis, Multidrug-Resistant (1)

Sponsors

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Centers for Disease Control and Prevention (1)  ·  Makerere University (1)  ·  Shanghai Pulmonary Hospital, Shanghai, China (1)  ·  University of Cape Town (1)  ·  University of Washington (1)

Countries

South Africa (5)  ·  Haiti (4)  ·  Kenya (4)  ·  Uganda (3)  ·  Botswana (2)  ·  Brazil (2)  ·  Peru (2)  ·  Thailand (2)  ·  Zimbabwe (2)  ·  India (1)  ·  Malawi (1)  ·  Mexico (1)  ·  Philippines (1)  ·  Vietnam (1)

Top investigators

Kelly Dooley, MD, PhD (2)  ·  Andreas H Diacon, MD, PhD (1)  ·  Anneke Hesseling, MD (1)  ·  Avy Violari, MD (1)  ·  Christine Sekaggya-Wiltshire, MBChB, PhD (1)  ·  Constance A Benson, MD (1)  ·  Grace John-Stewart, MD, PhD (1)  ·  Keertan Dheda, MBChB (1)  ·  Mark Cotton, MD (1)  ·  Radojka Savic, PharmD, PhD (1)  ·  Umesh Lalloo, MD, FRCP (1)

Results publications

PMID 31932382, PMID 31945300, PMID 31969368, PMID 32564076, PMID 34403326, PMID 35175905, PMID 35315690, PMID 35607710, PMID 36808186, PMID 38564365, PMID 38768617, PMID 40195983, PMID 40817073, PMID 41504451

NIH funding

U01AI068636 (1), UM1AI068636 (1)